Setting

Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country

Published: 29 Dec 2020 | Report Code: 10247819 | Pages: 136

Asia Pacific pharmaceutical CDMO market will grow by 8.3% annually with a total addressable market cap of $725.2 billion over 2020-2030 owing to the rising demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures. Highlighted with 44 tables and 53 figures, this 136-page report “Asia Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” is based on a comprehensive research of the entire Asia Pacific pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country. Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical Industry • Biopharmaceutical Industry Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Pharmaceutical Contract Manufacturing Organization (CMO) • Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing) • Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs) • Secondary Packaging Pharmaceutical Contract Research Organization (CRO) • CRO for Pre-clinical Development • CRO for Phase I Trials • CRO for Phase II Trials • CRO for Phase III Trials • CRO for Phase IV Trials • Laboratory Services • Consulting Services • Data Management Services Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Infectious Diseases • Oncology • Metabolic Disorders • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Gastrointestinal Disorders • Other Therapeutic Applications Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Pharmaceutical & Biopharmaceutical Companies • Medical Device Companies • Academic Institutes Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Company Profiles of CMO: Aenova Group Baxter BioPharma Solutions Boehringer Ingelheim Catalent Inc. Famar S.A. Hospira, Inc. Jubilant Life Sciences Ltd. Lonza Group Patheon Inc. Pfizer CentreSource Recipharm AB Vetter Pharma International GmbH 8.3.2 Company Profiles of CRO: Charles River Laboratories CMIC Co. Ltd Covance Inc. Hangzhou Tigermed Consulting Co Ltd ICON Plc IQVIA Holdings Inc. LSK Asia Pacific Pharma Service Co Ltd Novotech Pty Ltd PAREXEL International Corporation Pharmaceutical Product Development LLC (PPD) PRA Health Sciences Inc. Quanticate Ltd Samsung Bioepis Co. Ltd SGS SA (SGS Life Sciences) Syneos Health Inc. WuXi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents

1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	14
1.2.6 Market Size/Share Estimation	15
1.2.7 Research Limitations	16
1.3 Executive Summary	17
2 Market Overview and Dynamics	20
2.1 Market Size and Forecast	20
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	31
2.4 Emerging Opportunities and Market Trends	34
2.5 Porter’s Fiver Forces Analysis	38
3 Segmentation of Asia Pacific Market by Category	42
3.1 Market Overview by Category	42
3.2 Pharmaceutical Industry	44
3.3 Biopharmaceutical Industry	45
4 Segmentation of Asia Pacific Market by Service Type	46
4.1 Market Overview by Service Type	46
4.2 Pharmaceutical Contract Manufacturing Organization (CMO)	48
4.2.1 Active Pharmaceutical Ingredients (API)	49
4.2.2 Finished Dosage Formulations (FDF)	50
4.2.3 Secondary Packaging	52
4.3 Pharmaceutical Contract Research Organization (CRO)	53
4.3.1 CRO for Pre-clinical Development	55
4.3.2 CRO for Phase I Trials	56
4.3.3 CRO for Phase II Trials	57
4.3.4 CRO for Phase III Trials	58
4.3.5 CRO for Phase IV Trials	59
4.3.6 Laboratory Services	60
4.3.7 Consulting Services	61
4.3.8 Data Management Services	62
5 Segmentation of Asia Pacific Market by Therapeutic Application	63
5.1 Market Overview by Therapeutic Application	63
5.2 Infectious Diseases	65
5.3 Oncology	66
5.4 Metabolic Disorders	67
5.5 Cardiovascular Disorders	68
5.6 Central Nervous System	69
5.7 Pulmonary Disorders	70
5.8 Gastrointestinal Disorders	71
5.9 Other Therapeutic Applications	72
6 Segmentation of Asia Pacific Market by End User	73
6.1 Market Overview by End User	73
6.2 Pharmaceutical & Biopharmaceutical Companies	75
6.3 Medical Device Companies	76
6.4 Academic Institutes	77
7 Asia-Pacific Market 2019-2030 by Country	78
7.1 Overview of Asia-Pacific Market	78
7.2 Japan	81
7.3 China	84
7.4 Australia	86
7.5 India	88
7.6 South Korea	90
7.7 Rest of APAC Region	92
8 Competitive Landscape	94
8.1 Overview of Key Vendors	94
8.2 New Product Launch, Partnership, Investment, and M&A	98
8.3 Company Profiles	99
8.3.1 Company Profiles of CMO	99
Aenova Group	99
Baxter BioPharma Solutions	101
Boehringer Ingelheim	102
Catalent Inc.	103
Famar S.A.	104
Hospira, Inc.	105
Jubilant Life Sciences Ltd.	106
Lonza Group	107
Patheon Inc.	108
Pfizer CentreSource	109
Recipharm AB	110
Vetter Pharma International GmbH	111
8.3.2 Company Profiles of CRO	113
Charles River Laboratories	113
CMIC Co. Ltd	115
Covance Inc.	116
Hangzhou Tigermed Consulting Co Ltd	117
ICON Plc	118
IQVIA Holdings Inc.	119
LSK Asia Pacific Pharma Service Co Ltd	120
Novotech Pty Ltd	121
PAREXEL International Corporation	122
Pharmaceutical Product Development LLC (PPD)	123
PRA Health Sciences Inc.	124
Quanticate Ltd	125
Samsung Bioepis Co. Ltd	126
SGS SA (SGS Life Sciences)	127
Syneos Health Inc.	128
WuXi AppTec Inc.	129
9 Investing in Asia Pacific Market: Risk Assessment and Management	130
9.1 Risk Evaluation of Asia Pacific Market	130
9.2 Critical Success Factors (CSFs)	133
Related Reports and Products	136
List Of Tables

Table 1.  Snapshot of Asia Pacific Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030	18
Table 2. Growth Rate of World Real GDP, 2017-2021	22
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn	28
Table 4. Worldwide Total Number of Registered Clinical Trials	30
Table 5.  Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical CDMO Market	34
Table 6. Asia Pacific Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	42
Table 7. Asia Pacific Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	46
Table 8. Asia Pacific Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn	48
Table 9. Asia Pacific Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn	49
Table 10. Asia Pacific Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn	51
Table 11. Asia Pacific Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn	54
Table 12. Asia Pacific Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	63
Table 13. Asia Pacific Pharmaceutical CDMO Market by End User, 2019-2030, $ bn	73
Table 14. APAC Pharmaceutical CDMO Market by Country, 2019-2030, $ bn	79
Table 15. Japan Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	83
Table 16. Japan Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	83
Table 17. Japan Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	83
Table 18. China Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	85
Table 19. China Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	85
Table 20. China Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	85
Table 21. Australia Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	87
Table 22. Australia Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	87
Table 23. Australia Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	87
Table 24. India Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	89
Table 25. India Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	89
Table 26. India Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	89
Table 27. South Korea Pharmaceutical CDMO Market by Category, 2019-2030, $ bn	91
Table 28. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn	91
Table 29. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn	91
Table 30. Pharmaceutical CDMO Market in Rest of APAC by Country, 2019-2030, $ bn	93
Table 31. Breakdown of World CMO Market by Key Vendor, 2019, %	96
Table 32. Breakdown of World CRO Market by Key Vendor, 2019, %	96
Table 33. Aenova Group: Company Snapshot	99
Table 34. Aenova Group: Business Segmentation	99
Table 35. Aenova Group: Product Portfolio	100
Table 36. Aenova Group: Revenue, 2016-2018, $ bn	100
Table 37. Aenova Group: Recent Developments	100
Table 38. Charles River Laboratories: Company Snapshot	113
Table 39. Charles River Laboratories: Business Segmentation	113
Table 40. Charles River Laboratories: Product Portfolio	114
Table 41. Charles River Laboratories: Revenue, 2016-2018, $ bn	114
Table 42. Charles River Laboratories: Recent Developments	114
Table 43.  Risk Evaluation for Investing in Asia Pacific Market, 2019-2030	131
Table 44. Critical Success Factors and Key Takeaways	134
List Of Figures

Figure 1. Research Method Flow Chart	11
Figure 2. Breakdown of Primary Research	13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation	15
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	17
Figure 5. Asia Pacific Pharmaceutical CDMO Market, 2019-2030, $ bn	20
Figure 6. Impact of COVID-19 on Business	24
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical CDMO Market	26
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical CDMO Market	31
Figure 9. Investment Opportunity Analysis	35
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical CDMO Market	38
Figure 11. Breakdown of Asia Pacific Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue	42
Figure 12. Asia Pacific Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)	43
Figure 13. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn	44
Figure 14. Asia Pacific Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn	45
Figure 15. Breakdown of Asia Pacific Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue	46
Figure 16. Asia Pacific Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%)	47
Figure 17. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn	48
Figure 18. Asia Pacific Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn	49
Figure 19. Asia Pacific Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn	50
Figure 20. Asia Pacific Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn	52
Figure 21. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn	53
Figure 22. Asia Pacific Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn	55
Figure 23. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn	56
Figure 24. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn	57
Figure 25. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn	58
Figure 26. Asia Pacific Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn	59
Figure 27. Asia Pacific Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn	60
Figure 28. Asia Pacific Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn	61
Figure 29. Asia Pacific Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn	62
Figure 30. Breakdown of Asia Pacific Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue	64
Figure 31. Asia Pacific Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)	64
Figure 32. Asia Pacific Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn	65
Figure 33. Asia Pacific Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn	66
Figure 34. Asia Pacific Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn	67
Figure 35. Asia Pacific Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn	68
Figure 36. Asia Pacific Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn	69
Figure 37. Asia Pacific Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn	70
Figure 38. Asia Pacific Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn	71
Figure 39. Asia Pacific Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn	72
Figure 40. Breakdown of Asia Pacific Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue	73
Figure 41. Asia Pacific Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%)	74
Figure 42. Asia Pacific Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn	75
Figure 43. Asia Pacific Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn	76
Figure 44. Asia Pacific Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn	77
Figure 45. Breakdown of APAC Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue	79
Figure 46. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)	80
Figure 47.  Pharmaceutical CDMO Market in Japan, 2019-2030, $ bn	82
Figure 48.  Pharmaceutical CDMO Market in China, 2019-2030, $ bn	84
Figure 49.  Pharmaceutical CDMO Market in Australia, 2019-2030, $ bn	86
Figure 50.  Pharmaceutical CDMO Market in India, 2019-2030, $ bn	88
Figure 51.  Pharmaceutical CDMO Market in South Korea, 2019-2030, $ bn	90
Figure 52.  Pharmaceutical CDMO Market in Rest of APAC, 2019-2030, $ bn	92
Figure 53. Growth Stage of Asia Pacific Pharmaceutical CDMO Industry over the Forecast Period	94


Key Players (this may not be a complete list and extra companies can be added upon request): 
Company Profiles of CMO:
Aenova Group	
Baxter BioPharma Solutions	
Boehringer Ingelheim	
Catalent Inc.	
Famar S.A.	
Hospira, Inc.
Jubilant Life Sciences Ltd.	
Lonza Group	
Patheon Inc.	
Pfizer CentreSource	
Recipharm AB	
Vetter Pharma International GmbH	
8.3.2 Company Profiles of CRO:
Charles River Laboratories	
CMIC Co. Ltd	
Covance Inc.	
Hangzhou Tigermed Consulting Co Ltd	
ICON Plc	
IQVIA Holdings Inc.	
LSK Global Pharma Service Co Ltd	
Novotech Pty Ltd	
PAREXEL International Corporation	
Pharmaceutical Product Development LLC (PPD)	
PRA Health Sciences Inc.	
Quanticate Ltd	
Samsung Bioepis Co. Ltd	
SGS SA (SGS Life Sciences)	
Syneos Health Inc.	
WuXi AppTec Inc.